Uterus Adenosarkomları: On Üç Olgunun Klinikopatolojik Değerlendirmesi

Year 2021, Volume: 10 Issue: 1, 18 - 24, 30.04.2021

Duygu Ayaz Sevil Sayhan Dudu Solakoğlu Kahraman Volkan Karataşlı

https://doi.org/10.47493/abantmedj.2021.28

Abstract

Uterus Adenosarkomları: 13 olgunun klinikopatolojik değerlendirmesi
AMAÇ:Müllerian adenosarkomlar, çoğunlukla uterusta görülen, benign epitelial ve malign mezenkimal komponentten oluşan nadir bifazik tümörlerdir.Bu çalışmada uterus adenosarkomlarının klinik ve histopatolojik özelliklerini gözden geçirmeyi amaçladık. GeREÇ VE YÖNTEMLER:.Çalışmamızda, 1 Ocak 2009-1 Ocak 2020 tarihleri arasında tanı alan uterus adenosarkom olgularının klinik verileri tıbbi kayıtlar gözden geçirilerek elde edildi. Patoloji speysmenleri ise tekrar incelendi. BULGULAR: Hastanemizde tanı alan, tedavi takibi yapılan 13 uterin adenosarkom olgusunu çalışmaya dahil ettik.Tümörlerin tümünün endometriumdan köken aldığı izlenirken hastaların %69.2’si tanı anında 1. evredeydi. Hastaların %69.3’ünde evreleme yapıldı.Olguların %69.2’sinde mezenkimal komponenet yüksek dereceli olup tümünde sarkomatöz aşırı büyüme dikkati çekti.SONUÇ: Literatürle uyumlu olarak sarkomatöz aşırı büyüme, derin myometrial invazyon ve heterolog komponent varlığının, kısa sağkalım süreleriyle ilişkili olduğunu saptadık.

Anahtar sözcükler: Müllerian adenosarkom, uterus, sarkomatöz aşırı büyüme
Uterine Adenosarcoma: Clinicopathological evaluation of 13 cases

OBJECTIVE: Mullerian adenosarcomas are rare biphasic tumors mostly seen in the uterus, consisting of benign epithelial and malignant mesenchymal components. In this study, we aimed to review the clinical and histopathological features of uterine adenosarcoma. MATERIAL AND METHODS: In our study, clinical data of ureus adenosarcoma cases diagnosed between 1 January 2009 and 1 January 2020 were obtained by reviewing medical records. Pathology speysmenelri were examined again. RESULTS. We included 13 uterine adenosarcoma cases diagnosed in our hospital and followed-up. While all tumors originated from the endometrium, 69.2% of the patients were in the first stage at the time of diagnosis. Staging was performed in 69.2% of patients. Mesenchymal component was high in 69.2% of cases, and sarcomatous overgrowth was noted in all. CONCLUSION: In accordance with the literature, we found that the presence of sarcomatous overgrowth, deep myometrial invasion and heterologous component was associated with short survival times.

Keywords: Mullerian adenosarcoma, uterus, sarcomatous overgrowth

Keywords

, uterus, Müllerian adenosarkom, sarkomatoid aşırı büyüme

References

• 1.Carroll A, Ramirez PT, Westin SN, Soliman PT, Munsell MF, Nick AM, Schmeler KM, Klopp AH, Fleming ND. Uterine adenosarcoma: An analysis on management, outcomes, and risk factors for recurrence. Gynecologic Oncology 2014;135:455-461.
• 2.Arend R, Bagaria M, Lewin SN, Sun X, Deutsh I, Burke WM, Herzog JD. Long-term outcome and natural history of uterine adenosarcomas. Gynecologic Oncology 2010;119:305-308.
• 3.Taga M, Sawada M, Nagai A, Yamamoto D, Hayase R. A case of Adenosarcoma of the Uterus. Case report Obstet Gynecol 2014;2014:342187.
• 4.Yuan Z, Yu M, Shen K, Yang J, Cao D, Zhang Y, Zhou H, Wu H. Uterine Adenosarcoma: A retrospective 12-year single-center study. Frontiers in Oncology 2019;9(237): 1-8.
• 5.Hanyuan Liu BS, Zhen Shen MS, Dabao Wu BS, Ying Zhou MD. Uterine adenosarcoma with sarcomatous overgrowth: A case report of aggressive disease in a 16-year-old girl and literature review. J. Pediatr Adolesc Gynecol 2018;31:426-431.
• 6.Seagle BL, Kanis MStrohl AE, ShahabibS. Survival of woman with Mullerian adenosarcoma: a National Cancer Database study. Gynecol Oncol 2016;143:636-641.
• 7.Shi Y, Liu Z, Peng Z, Yang K, Yao X. The diagnosii and treatment of Mullerian adenosarcoma of the uterus. Australian and New Zealand Journal of Obstetrics and Gynaecology 2008;48:596-600.
• 8.Tanner EJ, Toussaint T, Leitao Jr MM, Hensley ML, Soslow RA, Gardner GJ, et al. Management of uterine adenosarcomas with and without sarcomatous owergrowth. Gynecol Oncol 2013;129:140-144.
• 9.Özgü E, Narin MA, Yalçın HR, Taşçı T, Güngör T, Çavuşoğlu D, Meydanlı MM, Tulunay G. Uterine adenosarcomas: A dual-institution experience. Joournal of Obstetrcs and Gynaecology 2016;1-4.
• 10.Göktaş S, Yıldırım M, Süren D, Tutuş B, Dilli UD, Yıldız M. Uterus adenosarkomu: Olgu sunumu. Kocatepe Tıp Dergisi 2013;14:40-43.
• 11.Kefeli M, Yıldız L, Çelik H, Aydın O, Kandemir B. Uterin adenosarkom: Dört olgunun klinikopatolojik değerlendirmesi. Journal of Experimental and Clinical Medicine 2009;26:190-192.
• 12.Zaluodek CJ, Hendrickson MR, Soslow RA . Mesenchymal Tumors of the uterus. In Robert J Kurman,Lora H Ellenson, Brigitte M Ronnett (eds) Blaustein’s pathology of the female Genital Tract 6th edition Springer, New York, USA 2011:455-527.
• 13. Wells M, Oliva E, Palacios J, Prat J. Mixed epithelial and mesenchymal tumours. In Robert J. Kurman, Maria Luisa Carcangiu, C. Simon Herrington, Robert H. Young (eds) WHO Classification of Tumours of Female Reproductive Organs 4th edition IARC Lyon, France 2014:148-151.
• 14.Togami S, Kawamura T, Fukuda M, Yanazume S, Kamio M, Kobayashi H. Clinical management of uterine cervical mullerian adenosarcoma: A clinicopathological study of six cases and review of literature. Taiwanese Journal of obstetrics & Gynecology 2018;57:479-482.